947370-34-5

Basic information

• Product Name: (R-(E))-1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid cyclooctylammonium salt
• Synonyms: (R-(E))-1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid cyclooctylammonium salt
• CAS NO: 947370-34-5
• Molecular Weight: 713.424
• Mol File: 947370-34-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (R-(E))-1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid cyclooctylammonium salt(CAS DataBase Reference)
• NIST Chemistry Reference: (R-(E))-1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid cyclooctylammonium salt(947370-34-5)
• EPA Substance Registry System: (R-(E))-1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid cyclooctylammonium salt(947370-34-5)

Safety Data

• Hazardous Substances Data: 947370-34-5(Hazardous Substances Data)

Upstream product

• 5452-37-9 cyclooctylamine 
• 807638-71-7 2-[2-[3(S)-[3-[(1E)-2-(7-chloroquinoline-2-yl)ethenyl]phenyl]-3-methanesulfonyloxypropyl]phenyl]-2-propanol 
• 162515-68-6 1-(sulfanylmethyl)cyclopropaneacetic acid 
• 158966-92-8 montelukast 

Downstream Products

• 151767-02-1 Montelukast sodium 
• 1146137-52-1 (R-(E))-1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-methylethenyl)phenyl)propyl)thio)methyl)-cyclopropaneacetic acid sodium salt 
• 158966-92-8 montelukast 

Relevant articles and documents

PROCESS FOR PREPARING MONTELUKAST SODIUM CONTAINING CONTROLLED LEVELS OF IMPURITIES

The present invention is directed to a process of preparing montelukast or a salt thereof with minimal amounts of impurities, such as a dehydration impurity (compound (VI)) or a cyclic ether impurity (compound (VIII)).

PROCESS FOR PREPARING MONTELUKAST AND SALTS THEREOF USING OPTICALLY IMPURE 2-(2-(3(S)-(3-(7-CHLORO-2-QUINOLINYL)ETHENYL)PHENYL)-3-HYDROXYPROPYL)PHENYL-2-PROPANOL

A process for preparing montelukast and salts thereof using an optically impure 2-(2-(3(S)-(3-(7-chloro-2-quinolinyl)-ethenyl)-phenyl)-3-(hydroxylpropyl)phenyl)-2 propanol as starting material, which contains the (R)-enantiomer impurity in the range of greater than 0.5% to about 8.0% by weight, is disclosed. The process described herein using an optically impure material results in the final product, montelukast sodium, in optical purity of greater than 99.7% enantiomeric excess.

Process for preparing montelukast and salts thereof

The present invention provides a process for preparing highly pure montelukast and salts thereof by reacting the side-chain precursor 1-(mercaptomethyl)-cyclopropaneacetic acid with 2-(2-(3S)-(3-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-(methanesulfonyloxypropyl)phenyl-2-propanol in a solvent mixture containing a base.